RPRX Royalty Pharma plc | GB00BMVP7Y09
Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Latest News
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
GlobeNewswire • 07/22/2026
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma
PR Newswire • 07/22/2026
Royalty Pharma declares third quarter 2026 dividend
GlobeNewswire • 07/17/2026
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.royaltypharma.com |
| Audit Risk | 2 |
| Board Risk | 4 |
| Overall Risk | 6 |
| Market Cap | 33.88B |
| Trailing P/E | 30.96 |
| Forward P/E | 10.52 |
| Dividend Rate | 0.94 |
| Dividend Yield | 1.60% |
| Trailing Annual Div. Rate | 0.9 |
| Trailing Annual Div. Yield | 1.52% |
| Trailing EPS | 1.9 |
| Forward EPS | 5.59 |
| Book Value | 15.53 |
| Price-to-Book | 3.79 |
| Enterprise-to-Revenue | 15.36 |
| Short Ratio | 3.53 |
| Ex-Dividend Date | 08/14/2026 |
| Dividend Date | 09/10/2026 |
| Earnings Date | 08/05/2026 |
| Earnings Call Date | 08/05/2026 |
| Earnings Average | 1.27 |
| Earnings Low | 1.23 |
| Earnings High | 1.33 |
| Revenue Average | 758.88M |
| Revenue Low | 741.57M |
| Revenue High | 785.00M |